Key result
Multivariable global risk-guided blood pressure management optimizes treatment intensity to maximize absolute clinical benefit.
Why the study?
Does medical therapy to lower systolic blood pressure by 10 mm Hg reduce cardiovascular events in individuals with hypertension?
Does medical therapy to lower systolic blood pressure by 10 mm Hg reduce cardiovascular events in individuals with hypertension?
Answers are grounded in this paper and cite their sources.
Lowering systolic blood pressure by 10 mm Hg significantly reduces the risk of major cardiovascular events, reinforcing the importance of BP control in CVD prevention.
E levated blood pressure (BP) is a causal risk factor for cardiovascular disease (CVD). Epidemiological analyses have established the graded and continuous association between higher BP and CVD. Moreover, randomized clinical trials among individuals with hypertension have demonstrated, in aggregate, a reduction in CVD events by 20%, coronary heart disease (CHD) by 17%, stroke by 27%, and heart failure by 28% for every 10 mm Hg systolic BP (SBP) lowering with medical therapy. 1 Therefore, prevention, detection, treatment, and control of elevated BP, and its clinical correlate hypertension, is an important public health priority and a primary target for CVD prevention.
No takes yet. Share an insight, caveat, or question.
Karmali et al. (2017) conducted a review in Hypertension and Cardiovascular Disease. Global CVD risk assessment to guide BP management vs. Isolated blood pressure thresholds (standard care) was evaluated. Incorporating multivariable global cardiovascular risk assessment into blood pressure management guidelines can better match treatment intensity to a patient's absolute risk, maximizing clinical benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: